| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA283: Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion. |
|
Medicine details |
|
| Medicine name | ranibizumab (Lucentis®) |
| Formulation | 10 mg/ml solution for injection |
| Reference number | 553 |
| Indication | Treatment of visual impairment due to macular oedema secondary to retinal vein occlusion |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Eye |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 16/05/2011 |
| NICE guidance | |